Aaron K Olson, MD

Aaron K Olson, MD

Cardiology, Neuromuscular Program, Kawasaki Disease Clinic

On staff since July 2006

Academic Title: Associate Professor, Cardiology

Research Center: Center for Integrative Brain Research

"I go to work each day striving to make new discoveries in the basic science mechanisms controlling cardiovascular disease in children. I hope to translate these discoveries into new therapies for pediatric patients. "

  • Aaron Olson, MD, is an attending physician at Seattle Children’s Hospital and Assistant Professor in the Department of Pediatrics at the University of Washington School of Medicine. His clinical work is in general pediatric cardiology. His research interests include pharmacological clinical trials and metabolic regulation in the heart.

    • Related Pages

    • Olson Lab

      Olson Lab

      Dr. Aaron Olson is unraveling how changes in cardiac energy production affect heart function. Congenital heart disease and other cardiac problems change how the heart produces energy. While researchers know that these changes impact heart function, they don’t know the mechanisms of this interaction. By identifying

    • Stacey Marysville, WA 10.27.16

      Very informative doctor. He spent time with us discussing and answering all of our questions. He was kind and did not talk down to my child. Great doctor and he seemed genuinely happy to explain things so we understood everything.

    Recommend Aaron K Olson, MD

  • Other Publications

    • Choueiter NF, Olson AK, Shen DD, Portman MA
      Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease.
      20667551 The Journal of pediatrics, 2010 Dec. : 960-966.e1
    • Portman MA, Slee A, Olson AK, Cohen G, Karl T, Tong E, Hastings L, Patel H, Reinhartz O, Mott AR, Mainwaring R, Linam J, Danzi S
      Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary Bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis.
      20837917 Circulation, 2010 Sept. 14 : S224-33
    • Portman MA, Slee A, Olson AK, Cohen G, Karl T, Tong E, Hastings L, Patel H, Reinhartz O, Mott AR, Mainwaring R, Linam J, Danzi S
      Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary Bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis.
      20837917 Circulation, 2010 Sept. 14 : S224-33
    • Choueiter NF, Olson AK, Shen DD, Portman MA
      Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease.
      20667551 The Journal of pediatrics, 2010 July 26
    • Olson AK, Hyyti OM, Cohen GA, Ning XH, Sadilek M, Isern N, Portman MA
      Superior cardiac function via anaplerotic pyruvate in the immature swine heart after cardiopulmonary bypass and reperfusion.
      18849332 American journal of physiology. Heart and circulatory physiology, 2008 Dec. : H2315-20
    • Hyyti OM, Olson AK, Ge M, Ning XH, Buroker NE, Chung Y, Jue T, Portman MA
      Cardioselective dominant-negative thyroid hormone receptor (Delta337T) modulates myocardial metabolism and contractile efficiency.
      18523124 American journal of physiology. Endocrinology and metabolism, 2008 Aug. : E420-7
    • Olson AK, Protheroe KN, Scholz TD, Segar JL
      Activation of the mitogen-activated protein kinases and Akt in response to pulmonary artery banding in the fetal sheep heart is developmentally regulated.
      17878740 Neonatology, 2008 : 145-52
    • Olson AK, Protheroe KN, Segar JL, Scholz TD
      Mitogen-activated protein kinase activation and regulation in the pressure-loaded fetal ovine heart.
      16299265 American journal of physiology. Heart and circulatory physiology, 2006 April : H1587-95
    • Olson AK, Protheroe KN, Scholz TD, Segar JL
      The mitogen-activated protein kinases and Akt are developmentally regulated in the chronically anemic fetal sheep heart.
      16638585 Journal of the Society for Gynecologic Investigation, 2006 April : 157-65

    Show More Hide

  • Presentations Title Event Location Date
    Metabolic Substrate Utilization During C-Myc Induced Cardiac Hypertrophy July 1, 2009
  • Grant Title Grantor Amount Award Date
    The Marfan Trial- a Trial of Beta Blocker Therapy (Atenolol) vs. Angiotensin II Receptor Blocker Therapy (Losartan) in individuals with Marfan syndrome (MFS) National Institute of Health unknown Feb. 1, 2008
    Role of Fcgamma Receptor Polymorphisms in Determining IVIG Response in Kawasaki Disease Thrasher Foundation Jan. 1, 2008

Overview

Board Certification(s)

Pediatric Cardiology
Pediatrics

Medical/Professional School

University of Minnesota Medical School, Minneapolis, MN

Residency

University of Chicago School of Medicine, Chicago, IL

Clinical Interests

Neonatal heart disease

Research Focus Area

Cardiac Metabolism, Kawasaki Disease, Cardiac Hypertrophy, Genetic Cardiovascular Disease